Outlook Therapeutics (BST:41ON) - Prezzo delle azioni, notizie e analisi

41ON Panoramica delle azioni

Operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Maggiori dettagli

41ON analisi fondamentale
Punteggio fiocco di neve
Valutazione	0/6
Crescita futura	5/6
Prestazioni passate	0/6
Salute finanziaria	2/6
Dividendi	0/6

Premi

Si prevede che gli utili cresceranno del 61.33% all'anno

Analisi del rischio

Patrimonio netto negativo

Le azioni sono altamente illiquide

Realizza un fatturato inferiore a 1 milione di dollari ( $0 )

Gli azionisti sono stati sostanzialmente diluiti nell'ultimo anno

Outlook Therapeutics, Inc. Concorrenti

Heidelberg Pharma

XTRA:HPHA

€105.8m

2invest

XTRA:2INV

€62.7m

4SC

DB:VSC

€50.2m

Formycon

XTRA:FYB

€857.2m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Outlook Therapeutics
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$7.28
Massimo di 52 settimane	US$31.60
Minimo di 52 settimane	US$3.80
Beta	0.19
1Variazione di 1 mese	0%
Variazione a 3 mesi	n/a
Variazione di 1 anno	n/a
3Variazione a 3 anni	-78.23%
Variazione a 5 anni	-68.66%
Variazione dall'IPO	-94.56%

Notizie e aggiornamenti recenti

Recent updates

Rendimenti per gli azionisti

	41ON	DE Biotechs	DE Mercato
7D	0%	-1.1%	1.1%
1Y	n/a	-18.8%	7.2%

Ritorno vs Industria: Dati insufficienti per determinare come si è comportato 41ON rispetto al settore German Biotechs.

Rendimento vs Mercato: Dati insufficienti per determinare la performance di 41ON rispetto al mercato German.

Volatilità dei prezzi

Is 41ON's price volatile compared to industry and market?
41ON volatility
41ON Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.6%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Prezzo delle azioni stabile: 41ON non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: Dati insufficienti per determinare la variazione della volatilità di 41ON nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2010	24	Russ Trenary	www.outlooktherapeutics.com

Outlook Therapeutics, Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Outlook Therapeutics con la sua capitalizzazione di mercato?
41ON statistiche fondamentali
Capitalizzazione di mercato	€171.05m
Guadagni(TTM)	-€48.35m
Ricavi(TTM)	n/a

0.0x

Rapporto P/S

-3.5x

Rapporto P/E

41ON è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
41ON Conto economico (TTM)
Ricavi	US$0
Costo del fatturato	US$21.12m
Profitto lordo	-US$21.12m
Altre spese	US$30.38m
Guadagni	-US$51.50m

Ultimi guadagni dichiarati

Dec 31, 2023

Prossima data di guadagno

n/a

Utile per azione (EPS)	-2.31
Margine lordo	0.00%
Margine di profitto netto	0.00%
Rapporto debito/patrimonio netto	-150.1%

Come si è comportato 41ON nel lungo periodo?

Vedi performance storica e confronto

41ON Panoramica delle azioni

Premi

Analisi del rischio

Outlook Therapeutics, Inc. Concorrenti

XTRA:HPHA

€105.8m

XTRA:2INV

€62.7m

DB:VSC

€50.2m

XTRA:FYB

€857.2m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Outlook Therapeutics, Inc. Announces Preliminary Topline Results of Norse Eight Clinical Trial

Outlook Therapeutics Announces Completion of Enrollment in NORSE EIGHT Clinical Trial

Outlook Therapeutics, Inc. to Report Q3, 2024 Results on Aug 14, 2024

Outlook Therapeutics, Inc. Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD

Outlook Therapeutics, Inc. to Report Q2, 2024 Results on May 16, 2024

Outlook Therapeutics, Inc. announced that it has received $5.000002 million in funding from Syntone Ventures LLC

Recent updates

Outlook Therapeutics, Inc. Announces Preliminary Topline Results of Norse Eight Clinical Trial

Outlook Therapeutics Announces Completion of Enrollment in NORSE EIGHT Clinical Trial

Outlook Therapeutics, Inc. to Report Q3, 2024 Results on Aug 14, 2024

Outlook Therapeutics, Inc. Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD

Outlook Therapeutics, Inc. to Report Q2, 2024 Results on May 16, 2024

Outlook Therapeutics, Inc. announced that it has received $5.000002 million in funding from Syntone Ventures LLC

Outlook Therapeutics Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD

Outlook Therapeutics, Inc. announced that it has received $59.999961 million in funding from a group of investors

Outlook Therapeutics Announces Effective Date for 1-For-20 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement

No longer forecast to breakeven

Outlook Therapeutics, Inc., Annual General Meeting, Mar 07, 2024

Outlook Therapeutics, Inc. Doses First Subject in Norse Eight

Outlook Therapeutics Receives FDA Agreement under Special Protocol Assessment for 90 Day Non-Inferiority Study, NORSE EIGHT

Outlook Therapeutics, Inc. announced that it expects to receive $65 million in funding from a group of investors

Forecast breakeven date pushed back to 2026

Outlook Therapeutics, Inc. Submits Special Protocol Assessment (SPA) to FDA for Non-Inferiority Study of ONS-5010

Outlook Therapeutics, Inc. Announces Strategic Organizational Realignment

Outlook Therapeutics, Inc. Appoints Jedd Comiskey as Senior VP – Head of Europe

Pomerantz Law Firm Announces the Filing of A Class Action Against Outlook Therapeutics, Inc. and Certain Officers

Pomerantz Law Firm Announces the Filing of A Class Action Against Outlook Therapeutics, Inc. and Certain Officers

Outlook Therapeutics Receives Non-Compliance Notice from Nasdaq

Outlook Therapeutics, Inc. Provides Regulatory Update on FDA Review of ONS-5010 / LYTENAVA (bevacizumab-vikg) for the Treatment of Wet AMD

New major risk - Negative shareholders equity

Outlook Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $16.927904 million.

Outlook Therapeutics, Inc., Annual General Meeting, Mar 29, 2023

Outlook Therapeutics, Inc. Announces Executive Appointments

Outlook Therapeutics, Inc. announced that it expects to receive $30 million in funding from Streeterville Capital, LLC

Outlook Therapeutics, Inc. Announces Validation of Marketing Authorization Application by the European Medicines Agency for ONS-5010 as a Treatment for Wet AMD

Outlook Therapeutics, Inc. Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD

Outlook Therapeutics, Inc Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration

Outlook Therapeutics, Inc. Announces Appointment of Julia A. Haller as Board of Director

Outlook Therapeutics, Inc. Confirms Status of Biologics License Application Submission for ONS-5010

Outlook Therapeutics Provides Update on Biologics License Application (BLA) Submission for ONS-5010 as A Treatment for Wet AMD

Outlook Therapeutics, Inc Submits Biologics License Application to the U.S. Food and Drug Administration for ONS-5010 as a Treatment for Wet AMD

Outlook Therapeutics, Inc. Appoints Alicia Tozier as Senior Vice President of Marketing and Market Access

Independent Director recently bought €227k worth of stock

Outlook Therapeutics, Inc. Announces Appointment of Joel Prieve as Senior Vice President, Commercial Operations

Outlook Therapeutics, Inc., Annual General Meeting, Mar 23, 2022

Outlook Therapeutics, Inc., Annual General Meeting, Mar 23, 2022

Outlook Therapeutics, Inc. to Present Pivotal Data from NORSE TWO Trial at the 9th International Congress on OCT and OCT Angiography in Rome (ICOOR)/ FLORetina Symposia

Forecast to breakeven in 2024

Forecast to breakeven in 2024

Outlook Therapeutics Reports New Positive 12-Month Safety Data from Pivotal Phase 3 NORSE TWO Trial

Outlook Therapeutics Presents Positive NORSE THREE Safety Data for ONS-5010/LYTENAVA™

Outlook Therapeutics, Inc. Reports Positive Efficacy and Safety Data from Phase 3 NORSE TWO Trial of ONS-5010/LYTENAVA (bevacizumab-vikg) for the Treatment of Wet AMD

Forecast to breakeven in 2023

Outlook Therapeutics, Inc. Reports Completion of Patient Dosing in the ONS-5010 Pivotal Phase 3 NORSE TWO Trial

Forecast breakeven pushed back to 2024

Outlook Therapeutics, Inc. Provides Update on the Clinical Progress of ONS-5010 (Bevacizumab-Vikg) in Virtual Clinical Day

Outlook Therapeutics, Inc., Annual General Meeting, Mar 24, 2021

Chief Operating Officer recently sold €134k worth of stock

Outlook Therapeutics Reports Final Visit for Last Patient in Open-Label Safety Study for ONS-5010/LYTENAVA™

Outlook Therapeutics, Inc. Recent Financing Secures Funding to Support Ons-5010 / Lytenava™ Through Planne Bla Submission

New 90-day high: €1.39

New 90-day high: €1.07

Outlook Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

New 90-day high: €1.04

Outlook Therapeutics, Inc. Announces Board Appointments

Outlook Therapeutics, Inc. announced that it has received $10 million in funding